cannabis indica

Síndrome do Intestino Irritável

termo de indexação original: Irritable Bowel Syndrome

O acervo do Cannabis Indica reúne 94 estudos científicos que tocam a condição Síndrome do Intestino Irritável, publicados entre 2004 e 2024. Pela leitura automatizada, 73 (78%) foram classificados como favoráveis, 13 (14%) como inconclusivos e 8 (9%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (55 estudos), seguido de estudo em animais (18). Os compostos mais presentes são Anandamida (AEA), 2-Araquidonoilglicerol (2-AG) e Endocanabinoide (não especificado). Aparece com frequência ao lado de DII — Doença Inflamatória Intestinal, DII — Doença de Crohn e Inflamação.

Estudos indexados
94
Período coberto
2004–2024
Favoráveis
73 · 78%
Inconclusivos
13 · 14%
Desfavoráveis
8 · 9%
Termo original
Irritable Bowel Syndrome

O acervo em números

Tipo de estudo

Metanálise55
Estudo em Animais18
Ensaio Clínico Duplo-Cego10
Estudo Laboratorial6
Ensaio Clínico5

Direção do resultado

Favorável73
Inconclusivo13
Desfavorável8

Por década

2000s9
2010s48
2020s37

94 estudos

Filtrar e buscar no acervo →
  1. 2024

    Palmitoylethanolamide and polydatin in pediatric irritable bowel syndrome: A multicentric randomized controlled trial

    FavorávelEnsaio Clínico Duplo-CegoDorPalmitoiletanolamida (PEA)
  2. 2023

    Alteration of faecal microbiota balance related to long-term deep meditation

  3. 2023

    Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)

    FavorávelEnsaio Clínico Duplo-CegoDorDor — CrônicaConstipaçãoEndocanabinoide (não especificado)
  4. 2023

    Recurrent Severe Burns Due to Cannabinoid Hyperemesis Syndrome

  5. 2022

    Acute pancreatitis as a rare adverse event among cannabis users: A systematic review

    DesfavorávelMetanáliseDorInflamaçãoEfeitos Adversos da CannabisAnandamida (AEA)+16
  6. 2022

    Antispasmodic Effect of Bergamot Essential Oil on Rat Isolated Gut Tissues

    FavorávelEstudo LaboratorialInflamaçãoEndocanabinoide (não especificado)
  7. 2022

    Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors

  8. 2022

    Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department

  9. 2022

    Could Palmitoylethanolamide Be an Effective Treatment for Long-COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications

  10. 2022

    Differential Effects of D9 Tetrahydrocannabinol (THC)- and Cannabidiol (CBD)-Based Cannabinoid Treatments on Macrophage Immune Function In Vitro and on Gastrointestinal Inflammation in a Murine Model

  11. 2022

    E-cigarette vaping associated acute lung injury (EVALI): state of science and future research needs

    DesfavorávelMetanáliseCâncerAnsiedadeDoenças Cardiovasculares (DCV)+16
  12. 2022

    Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty

  13. 2022

    Herbal Approaches to Pediatric Functional Abdominal Pain

    InconclusivoMetanáliseDorInflamaçãoDor — CrônicaTHC Farmacêutico+10
  14. 2022

    Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies

  15. 2022

    Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies

    DesfavorávelMetanáliseDorCâncerInflamaçãoAnandamida (AEA)THC Farmacêutico+14
  16. 2022

    Medical Cannabis Use Patterns and Adverse Effects in Inflammatory Bowel Disease

  17. 2022

    Oxytocin acts centrally in the brain to improve leaky gut through the vagus nerve and a cannabinoid signaling in rats

    FavorávelEstudo em AnimaisAutismoGastroparesiaEndocanabinoide (não especificado)
  18. 2022

    Role of cannabis in inflammatory bowel diseases

  19. 2022

    Role of the Endocannabinoid System in the Regulation of Intestinal Homeostasis

  20. 2022

    Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome

  21. 2022

    The effects of collagen peptides on exercise-induced gastrointestinal stress: a randomized, controlled trial

  22. 2022

    Treatment of Ovarian Hyperstimulation Syndrome in a Mouse Model by Cannabidiol, an Angiogenesis Pathway Inhibitor

    FavorávelEstudo em AnimaisDorCâncerInflamação+16
  23. 2022

    Urinary Cannabis Metabolite Concentrations in Cannabis Hyperemesis Syndrome

  24. 2021

    Cannabidiol Use, Substitution for Medications, and Perceptions of Effectiveness in Women with Chronic Pelvic Pain

    FavorávelMetanáliseDorEfeitos Adversos da CannabisAnsiedade+8
  25. 2021

    Cannabinoid Receptors Overexpression in a Rat Model of Irritable Bowel Syndrome (IBS) after Treatment with a Ketogenic Diet

    FavorávelEstudo em AnimaisDieta
  26. 2021

    Cannabis and Autoimmunity: Possible Mechanisms of Action

  27. 2021

    Cannabis Use is Associated With Reduced 30-Day All-cause Readmission Among Hospitalized Patients With Irritable Bowel Syndrome: A Nationwide Analysis

    FavorávelMetanálise
  28. 2021

    Effects of Cannabidiol Chewing Gum on Perceived Pain and Well-Being of Irritable Bowel Syndrome Patients: A Placebo-Controlled Crossover Exploratory Intervention Study with Symptom-Driven Dosing

    InconclusivoEnsaio Clínico Duplo-Cego
  29. 2021

    Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review

  30. 2021

    Experimental therapies in Irritable Bowel Syndrome

  31. 2021

    Genetic Variants of Fatty Acid Amide Hydrolase Modulate Acute Inflammatory Responses to Colitis in Adult Male Mice

  32. 2020

    An Overview of Cannabis Based Treatment in Crohn's Disease

  33. 2020

    Capsaicin Is a Negative Allosteric Modulator of the 5-HT3 Receptor

    FavorávelEstudo LaboratorialDorAnsiedadeDepressãoCapsaicina (CAPS)+2
  34. 2020

    Endocannabinoid system in irritable bowel syndrome and cannabis as a therapy

    FavorávelMetanáliseEndocanabinoide (não especificado)
  35. 2020

    Endocannabinoids Inhibit the Induction of Virulence in Enteric Pathogens

  36. 2020

    Enterocolic increase of cannabinoid receptor type 1 and type 2 and clinical improvement after probiotic administration in dogs with chronic signs of colonic dysmotility without mucosal inflammatory changes

    FavorávelEstudo em AnimaisAplicações VeterináriasMicrobioma
  37. 2020

    Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment

    FavorávelMetanálisePalmitoiletanolamida (PEA)
  38. 2019

    A Novel Standardized Cannabis sativa L. Extract and Its Constituent Cannabidiol Inhibit Human Polymorphonuclear Leukocyte Functions

    FavorávelEstudo LaboratorialDorInflamaçãoDoenças Cardiovasculares (DCV)+7
  39. 2019

    Can we teach old drugs new tricks?-Repurposing of neuropharmacological drugs for inflammatory skin diseases

    FavorávelMetanáliseInflamaçãoDepressãoEpilepsia+14
  40. 2019

    Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.

  41. 2019

    Cannabinoid Attenuation of Intestinal Inflammation in Chronic SIV-Infected Rhesus Macaques Involves T Cell Modulation and Differential Expression of Micro-RNAs and Pro-inflammatory Genes

  42. 2019

    Cannabis and Turmeric as Complementary Treatments for IBD and Other Digestive Diseases.

    FavorávelMetanáliseDII — Doença Inflamatória IntestinalCúrcuma
  43. 2019

    Cannabis use disorders may protect against certain disorders of the digestive organs in people with schizophrenia but not in healthy controls

  44. 2019

    Cannabis use disorders may protect against certain disorders of the digestive organs in people with schizophrenia but not in healthy controls

    InconclusivoMetanáliseDependência — CannabisPsicoseEsquizofrenia
  45. 2019

    Effect of a short-term low fermentable oligiosaccharide, disaccharide, monosaccharide and polyol (FODMAP) diet on exercise-related gastrointestinal symptoms

    FavorávelEnsaio ClínicoEstresse OxidativoProteína Ligadora de Ácidos Graxos (FABP)
  46. 2019

    Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis

  47. 2019

    Higher odds of irritable bowel syndrome among hospitalized patients using cannabis: a propensity-matched analysis

    InconclusivoMetanáliseEfeitos Adversos da Cannabis
  48. 2019

    Insights into the role of cannabis in the management of inflammatory bowel disease

  49. 2019

    The Endocannabinoid System of Animals

  50. 2018

    Cannabinoid pharmacology and therapy in gut disorders

    FavorávelMetanáliseCâncerNáusea e VômitoCâncer — Cólon
  51. 2018

    Cannabis and pediatric inflammatory bowel disease: change blossoms a mile high.

  52. 2018

    Dietary Geraniol Ameliorates Intestinal Dysbiosis and Relieves Symptoms in Irritable Bowel Syndrome Patients: A Pilot Study

    FavorávelEnsaio Clínico
  53. 2018

    Fatty acid amide hydrolase (FAAH) blockade ameliorates experimental colitis by altering microRNA expression and suppressing inflammation.

  54. 2018

    Herbs and Spices in the Treatment of Functional Gastrointestinal Disorders: A Review of Clinical Trials

    InconclusivoMetanáliseDor
  55. 2018

    The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information: Commissioned by the Crohn's and Colitis Foundation.

  56. 2018

    The therapeutic effects of Cannabis and cannabinoids: An update from the National Academies of Sciences, Engineering and Medicine report.

    FavorávelMetanáliseDorAnsiedadeDor — Crônica+7
  57. 2018

    The Use of Cannabinoids in Colitis: A Systematic Review and Meta-Analysis.

  58. 2017

    Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

  59. 2017

    Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial

    InconclusivoEnsaio Clínico Duplo-CegoDII — Doença Inflamatória IntestinalDII — Doença de Crohn
  60. 2017

    Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review.

  61. 2017

    Medical cannabis: Another piece in the mosaic of autoimmunity?

    FavorávelMetanáliseInflamaçãoEsclerose MúltiplaDiabetes+3
  62. 2017

    Prevalence and Patterns of Marijuana Use in Young Adults With Inflammatory Bowel Disease.

  63. 2017

    Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome

    FavorávelEnsaio Clínico Duplo-CegoSíndrome de Ativação MastocitáriaOutros Compostos Relacionados
  64. 2017

    The Anti-Inflammatory Effect and Intestinal Barrier Protection of HU210 Differentially Depend on TLR4 Signaling in Dextran Sulfate Sodium-Induced Murine Colitis

  65. 2016

    An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse.

  66. 2016

    Cannabinoids and autoimmune diseases: A systematic review

    FavorávelMetanáliseInflamaçãoEsclerose MúltiplaDiabetes
  67. 2016

    Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes

  68. 2016

    Efficacy, tolerability, and safety of cannabinoids in gastroenterology: A systematic review.

  69. 2016

    Endocannabinoids in the gastrointestinal tract

  70. 2016

    The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease.

  71. 2016

    Therapeutic Use of Cannabis in Inflammatory Bowel Disease.

  72. 2015

    AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner

  73. 2015

    Effects of Cannabinoids on T-cell Function and Resistance to Infection.

  74. 2014

    Cannabis for inflammatory bowel disease.

  75. 2014

    Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system

  76. 2014

    Clinical Endocannabinoid Deficiency (CECD) Revisited: Can This Concept Explain the Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and Other Treatment-Resistant Conditions?

    InconclusivoMetanáliseEnxaquecaFibromialgiaEndocanabinoide (não especificado)
  77. 2014

    Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH)

  78. 2014

    Geraniol-a Flavoring Agent With Multifunctional Effects in Protecting the Gastric and Duodenal Mucosa

    FavorávelEstudo em AnimaisDII — Doença Inflamatória IntestinalDII — Doença de Crohn
  79. 2013

    Cannabidiol in inflammatory bowel diseases: a brief overview.

  80. 2013

    Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study

    FavorávelEnsaio Clínico Duplo-CegoDII — Doença Inflamatória IntestinalDII — Doença de Crohn
  81. 2013

    Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study

    DesfavorávelEnsaio ClínicoDorAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
  82. 2012

    Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study

    FavorávelEnsaio ClínicoInflamaçãoDII — Doença de Crohn
  83. 2012

    Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea

    InconclusivoEnsaio Clínico Duplo-CegoDiarreiaTetraidrocanabinol (THC)Hidrolase de Amidas de Ácidos Graxos (FAAH)
  84. 2011

    Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome

  85. 2011

    The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients

    InconclusivoEnsaio Clínico Duplo-CegoHemorroidasTHC Farmacêutico
  86. 2009

    CB1 Receptors Mediate the Analgesic Effects of Cannabinoids on Colorectal Distension-Induced Visceral Pain in Rodents

  87. 2008

    Clinical Endocannabinoid Deficiency (CECD): Can This Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and Other Treatment-Resistant Conditions?

    InconclusivoMetanáliseEnxaquecaFibromialgiaEndocanabinoide (não especificado)
  88. 2008

    Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors.

  89. 2008

    Targeting the endocannabinoid system: to enhance or reduce?

  90. 2008

    Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide

  91. 2007

    Cannabinoid Type 1 Receptor Modulates Intestinal Propulsion by an Attenuation of Intestinal Motor Responses Within the Myenteric Part of the Peristaltic Reflex

    FavorávelEstudo LaboratorialDII — Doença de CrohnAnandamida (AEA)Canabinoides Sintéticos AM-x
  92. 2007

    Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors

  93. 2006

    The cannabinergic system as a target for anti-inflammatory therapies.

  94. 2004

    Involvement of cannabinoid receptors in gut motility and visceral perception

Continue por aqui

Perguntas frequentes

Quantos estudos sobre síndrome do intestino irritável estão indexados no acervo?
São 94 estudos, publicados entre 2004 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 55 · Estudo em Animais: 18 · Ensaio Clínico Duplo-Cego: 10 · Estudo Laboratorial: 6 · Ensaio Clínico: 5. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 73 favoráveis, 13 inconclusivos e 8 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Síndrome do Intestino Irritável — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/condicao/sindrome-do-intestino-irritavel/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Síndrome do Intestino Irritável — estudos científicos sobre cannabis. https://cannabisindica.com.br/condicao/sindrome-do-intestino-irritavel/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.